Generic tetrabenazine approval date?

See the DrugPatentWatch profile for tetrabenazine

When was generic tetrabenazine approved?

The U.S. Food and Drug Administration (FDA) approved the first generic version of tetrabenazine in April 2020 [1].

What is tetrabenazine used for?

Tetrabenazine is a medication used to treat chorea, involuntary jerky movements, associated with Huntington's disease [2].

How does generic tetrabenazine differ from the brand name?

Generic drugs contain the same active ingredient as their brand-name counterparts and are approved by the FDA to be safe and effective [3]. They are typically prescribed as alternatives when they meet the same standards of quality, strength, and performance [3].

What is the expected patent expiry for tetrabenazine?

Information regarding specific patent expiry dates for tetrabenazine and its generics can be found through resources that track drug patents. DrugPatentWatch.com provides details on patent information, which can indicate when market exclusivity is expected to end for various medications [4].

Are there other treatments for chorea in Huntington's disease?

While tetrabenazine is a primary treatment for chorea, research continues into other therapeutic approaches. The development of new drugs and therapies for neurodegenerative conditions is an ongoing area of pharmaceutical research.